Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMN 111 in infants and young children with achondroplasia at risk of cervicomedullary decompression surgery
2020-001055-40Phase 2Unknown
- Sponsor
- BioMarin Pharmaceutical Inc.
- Start
- May 2020
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of vosoritide in achondroplasia (ACH) (3 arms), sponsored by BioMarin Pharmaceutical Inc. Primary endpoint: Safety. Status: unknown.
02
Drugs
vosoritide
03
Conditions
achondroplasia (ACH)
Beyond the preview
Go deeper on 2020-001055-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001055-40.